12/02/14 - 04:34 PM EST
Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.READ FULL POST
12/01/14 - 11:37 AM EST
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.READ FULL POST
11/24/14 - 09:39 AM EST
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.READ FULL POST
11/19/14 - 01:25 PM EST
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.READ FULL POST
11/18/14 - 10:16 AM EST
Using stem cells to repair damaged hearts is a great story, but proof remains elusive.READ FULL POST
11/13/14 - 04:34 PM EST
J&J is paying $35 million upfront to Geron for rights to the drug.READ FULL POST
11/10/14 - 10:40 AM EST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'READ FULL POST
11/06/14 - 11:31 AM EST
The new clinical data on Bluebird's gene therapy are contained in a just-released abstract ahead of next month's American Society of Hematology annual meeting.READ FULL POST
11/06/14 - 11:12 AM EST
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.READ FULL POST
11/06/14 - 09:57 AM EST
The new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.